This DSIR recognition for company's in-house R&D Unit make it eligible for receiving funds for R&D purpose from various government departments and agencies
The drug will be manufactured at the group’s formulation manufacturing facility at Moraiya, Ahmedabad, India
The company remains committed to maintain the highest standards of compliance and will work closely with the agency to comprehensively address all the observations
APAC to see a reduction in imported surgical robotics
Under the soon to be launched Heal in India initiative, India aims to provide its health infrastructure for patients abroad and make it a global hub for medical and value-based healthcare for patients from across the world
Dr. Reddy’s will manufacture the Active Pharmaceutical Ingredient and finished drug at its facilities approved by USFDA
The cardiomyopathies market in the 68M is set to grow at a CAGR of 12.1%
Exceeding the target of 1.50 lakh Ayushman Bharat - Health & Wellness Centres (AB-HWC) by 31 December, 2022, more than 1.54 lakh Sub Health Centres and Primary Health Centres have been transformed as AB-HWCs
The company was chosen for this transformative exercise due to its deep expertise in the healthcare vertical, coupled with its digital engineering and cloud capabilities, a vast partner network, and long-term relationship with the client
Subscribe To Our Newsletter & Stay Updated
